Shares Spectrum Pharmaceuticals (NASDAQ:SPPI) are plunging in today’s trading after scientists from the U.S. Food and Drug Administration (FDA) raised concerns over the data shared by the company for poziotinib for the treatment of non-small cell lung cancer (NSCLC).
While the meeting of the advisory committee is scheduled for later this week, scientists from the regulator have flagged a low overall response rate as indicated by the data.
Moreover, concerns remain about dosage optimization and the safety profile of the drug as well.
Read full Disclosure
